Hefei Lifeon Pharmaceutical (003020.SZ): The marketing authorization application for clinical trials of Celecoxib and Tramadol Hydrochloride Tablets has been accepted.

Hefei Lifeon Pharmaceutical (003020.SZ) announced that recently, the company received the "Notice of Acceptance" for the marketing authorization application for clinical trials of Celecoxib and Tramadol Hydrochloride Tablets issued by the National Medical Products Administration. Celecoxib and Tramadol Hydrochloride Tablets are a co-crystal formed by the opioid agonist tramadol hydrochloride and the non-steroidal anti-inflammatory drug celecoxib. The proposed indication for this marketing authorization application for clinical trials is: suitable for the treatment of short-term moderate to severe acute somatic pain in adults. Moderate to severe somatic pain includes postoperative pain (such as after orthopedic and trauma surgery, or after dental surgery) or musculoskeletal pain (injury to muscles, ligaments, tendons, and joints).